Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting LDL-C ≥ 70 mg/dL~* High cardiovascular risk (diagnosis of HeFH or ASCVD)~* Be on maximally tolerated lipid-modifying therapy~Exclusion Criteria:~* Total fasting triglyceride ≥500 mg/dL~* Renal dysfunction or nephrotic syndrome or history of nephritis~* Body Mass Index (BMI) ≥50kg/m2~* Significant cardiovascular disease or cardiovascular event in the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ETC-1002 (Type: EXPERIMENTAL): ETC-1002 180 mg/day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).